Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
16 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Depression strongly predicts absenteeism among patients with chronic constipation

17 Jan 2017

Absenteeism among patients with chronic constipation appear to have a stronger association with depression than symptom severity, according to a recent study, suggesting that a portion of the indirect costs of chronic constipation is attributable to depression.

Researchers examined 148 consecutive patients with chronic constipation (mean age 43 years; 87 percent female) to determine the patient characteristics associated with increased absenteeism and Emergency Department (ED) utilization.

Disease severity, quality of life, somatization and psychiatric comorbidities were assessed using standardized instruments. Multivariable logistic regression facilitated identification of the predictors of work and school absenteeism, as well as ED visits for constipation.

Of the patients, 21.6 percent had high absenteeism, and 24.3 percent visited the ED for constipation in the past year. Chronically constipated patients with high absenteeism and ED visits were more likely to be depressed (56.3 vs 18.5 percent for high absenteeism; p<0.0001; 47.2 vs 19.6 for ED visits; p<0.01).

On analyses, depression was associated with a 4.41-fold increase in the risk of absenteeism (p<0.01). Additionally, a trend toward an association between depression and ED visits (OR, 2.57; p=0.067) was observed.

There was no association between symptom severity and high absenteeism or ED utilization.

The present data suggest that depression, but not symptom severity, strongly predicts absenteeism among patients with chronic constipation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
16 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.